Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Tysabri
Chronic inflammatory demyelinating polyneuropathy following malignant melanoma.
The ketogenic diet as a treatment paradigm for diverse neurological disorders.
Effects of functional electrical stimulation on gait function and quality of life for people with multiple sclerosis taking dalfampridine.
Different effects of opioid antagonists on mu-, delta-, and kappa-opioid receptors with and without agonist pretreatment.
UVB light attenuates the systemic immune response in CNS autoimmunity.
Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial.
Stabilization of rapidly worsening multiple sclerosis for 36 months in patients treated with interferon beta plus cyclophosphamide followed by interferon beta.
Magnetic resonance imaging in multiple sclerosis - patients' experiences, information interests and responses to an education programme.
Acute disseminated encephalomyelitis--a prospective study of clinical profile and in-hospital outcome predictors.
Inhibition of Neuronal Degenerin/Epithelial Na+ Channels by the Multiple Sclerosis Drug 4-Aminopyridine.
Benign Multiple Sclerosis: Does it exist?
Vitamin D status is positively correlated with regulatory T cell function in patients with multiple sclerosis.
Tobacco smoking, but not Swedish snuff use, increases the risk of multiple sclerosis.
Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS.
Laquinimod reduces neuroaxonal injury through inhibiting microglial activation.
American Academy of Neurology Annual Meeting
Eicosapentaenoic acid (EPA) induces peroxisome proliferator-activated receptors and ameliorates experimental autoimmune encephalomyelitis.
Microvesicles: novel biomarkers for neurological disorders.
Topical Application of Fingolimod Perturbs Cutaneous Inflammation.
A telerehabilitation program by virtual reality-video games improves balance and postural control in multiple sclerosis patients.
A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy.
Early Growth Response Gene-2 Controls IL-17 Expression and Th17 Differentiation by Negatively Regulating Batf.
Active Biotech announce that European Medicines Agency accepts start of scientific review of the marketing authorization application for laquinimod in relapsing-remitting multiple sclerosis
The age-range of risk of developing multiple sclerosis: evidence from a migrant population in Australia.

Pages